Randomized trial · people

Semaglutide: 6.6% vs 8.9% heart or stroke events in SUSTAIN-6

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In people with type 2 diabetes and high heart risk, semaglutide did not add heart risk and had fewer combined heart and stroke events than placebo, though eye complications rose.

Kind
Randomized trial
Studied in
People
Number studied
3297
Published
2016
Journal
N Engl J Med

What they tested

Does weekly semaglutide raise the risk of major heart and stroke events in people with type 2 diabetes, compared with placebo?

How the study was done

A randomized, placebo-controlled trial in 3297 people with type 2 diabetes on standard care, given once-weekly semaglutide (0.5 mg or 1.0 mg arms) or placebo (an inactive look-alike treatment) for 104 weeks. The main goal was to show semaglutide was no worse than placebo (noninferiority), and 83.0% already had heart disease, kidney disease or both.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

The combined outcome of cardiovascular death, nonfatal heart attack or nonfatal stroke happened in 108 of 1648 people (6.6%) on semaglutide and 146 of 1649 (8.9%) on placebo, a hazard ratio (relative risk over time) of 0.74 (95% CI 0.58 to 0.95). Nonfatal stroke was lower at 1.6% vs 2.7% (hazard ratio 0.61); nonfatal heart attack was 2.9% vs 3.9% (hazard ratio 0.74, P=0.12, not significant); and cardiovascular death rates were similar. New or worsening kidney disease was less common on semaglutide, but serious eye complications from diabetic retinopathy (such as bleeding in the eye or blindness) were more common, with a hazard ratio of 1.76. Serious adverse events were fewer on semaglutide, but more people stopped treatment because of side effects, mostly stomach and gut problems.

What it doesn’t show

The trial was designed to rule out harm (noninferiority), not to prove benefit, it lasted 104 weeks, and most people had high cardiovascular risk. It was funded by Novo Nordisk.

The paper

Marso et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016.

The compound

More studies on Semaglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo